February 20, 2026
In late 2025, the U.S. Pharmacopeia (USP) reopened one of the most closely watched quality conversations in the U.S. cannabinoid research ecosystem: the republished draft USP General Chapter <1568>, Quality Considerations for Cannabis and Cannabis‑Derived Products for Clinical Research, published for comment in Pharmacopeial Forum (PF) 51(3) (Sept/Oct 2025). Alongside it, USP also republished an updated proposed Cannabidiol (CBD) monograph.
For sponsors, CROs, analytical labs, and suppliers supporting clinical investigations, the signal is clear: even without comprehensive federal legalization, expectations are converging around harmonized specifications, validated methods, and tight impurity/stability control for research-grade materials.
This article summarizes what’s driving renewed attention to USP <1568>, how it aligns with FDA’s clinical research quality expectations, and what practical procurement and quality-system updates research teams should prioritize in 2025–2026.
Focus keyword: USP 1568 cannabis quality 2025
USP’s decision to republish draft <1568> (PF 51(3)) matters because it brings a pharmacopeial quality framing to materials that have historically been sourced through a patchwork of state programs, limited federal research supply channels, and variable lab practices.
While USP chapters are not automatically “law,” they often become the default technical baseline used in:
USP’s public page noting the republished draft chapter and comment opportunity is here: https://www.usp.org/dietary-supplements-herbal-medicines/cannabis
The pairing of draft <1568> with an updated proposed CBD monograph is what makes PF 51(3) particularly consequential. Taken together, they suggest USP is continuing to build a framework where research products are evaluated with the same mindset used for other investigational drug materials: identity, strength, purity, quality attributes, and fitness for intended use.
A third-party summary of the republished proposed CBD monograph and its 2025 comment window is available here (industry source): https://www.gmp-compliance.org/gmp-news/update-on-the-usp-cbd-monograph
Even though USP <1568> is a USP standard-setting effort, it should be read in parallel with FDA’s final guidance for industry: Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.
FDA guidance landing page: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research-guidance-industry
Federal Register notice announcing availability of the final guidance (Jan 2023): https://www.federalregister.gov/documents/2023/01/24/2023-01286/cannabis-and-cannabis-derived-compounds-quality-considerations-for-clinical-research-guidance-for
FDA’s clinical research guidance emphasizes that sponsors must meet FDA requirements regardless of the source of botanical material, and it highlights typical CMC expectations: well-characterized starting materials, control of impurities, and robust testing methods.
USP <1568> is best understood as a practical “how-to” lens for sponsors and suppliers trying to demonstrate that discipline for research materials, especially when materials include multiple analytes of interest (e.g., cannabinoids, terpenes) and complex matrices.
FDA’s guidance also emphasizes that activities around growing/manufacturing for investigational use must comply with the Controlled Substances Act (CSA) and DEA requirements when THC thresholds are exceeded. That remains a key operational constraint for many clinical programs.
For DEA’s research supply transaction process and related requirements, see DEA Diversion’s information for registered growers (official): https://www.deadiversion.usdoj.gov/drugreg/marihuana.html
Draft <1568> is not just a scientific document—it can become a procurement checklist. Sponsors and CROs should expect increasing use of “USP-conformant” language in vendor qualification and protocol planning.
Below are the areas most likely to drive work in 2025–2026.
One of the biggest real-world pain points in research programs is that “potency testing” can be deceptively non-comparable across labs and methods—especially when the study material contains multiple cannabinoids and the matrix includes excipients, flavors, or complex botanical components.
USP <1568>’s directionally consistent message with modern validation expectations is: if you’re going to make clinical claims about dose, exposure, or product performance, your method must be fit for purpose.
In 2025–2026, protocols and quality agreements are increasingly expected to spell out validation characteristics for:
For global harmonization context, many organizations now map validation planning to the revised ICH framework, including ICH Q2(R2) (Validation of Analytical Procedures) and ICH Q14 (Analytical Procedure Development). The ICH Q2(R2) guideline PDF is here: https://database.ich.org/sites/default/files/ICH_Q2(R2)_Guideline_2023_1130.pdf
Sponsors often focus validation effort on primary cannabinoids and under-resource the rest. However, for research materials—especially inhaled routes or concentrated extracts—there is heightened sensitivity to:
USP’s broader compendial ecosystem can help define expectations for specific impurity classes. For example, USP <467> Residual Solvents is a commonly cited framework (official USP PDF excerpt): https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc-467-residual-solvents-ira-20190927.pdf
Research teams frequently treat stability as a post-procurement activity (“we’ll test at baseline and near the end”). In a USP-aligned world, stability planning should be part of the product definition.
At minimum, sponsors should be ready to justify:
Stability expectations are evolving across pharma more broadly, too. In April 2025, ICH advanced a consolidated draft stability guideline (ICH Q1) to Step 2b, reflecting a trend toward clearer, harmonized stability expectations. The ICH draft guideline is here: https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf and FDA’s Federal Register notice on the draft guidance is here: https://www.federalregister.gov/documents/2025/06/24/2025-11552/q1-stability-testing-of-drug-substances-and-drug-products-international-council-for-harmonisation
Operational takeaway: if your clinical trial depends on maintaining a narrow content range for a key analyte, you should design stability sampling points that match your actual distribution model (direct-to-site, central pharmacy, direct-to-participant where allowed).
Draft USP <1568> and the broader USP direction point toward research materials being evaluated with increasing scrutiny for impurity categories that have long been expected in conventional drug development.
While each program is different, sponsors should anticipate questions and auditing around:
USP’s elemental impurities limits chapter <232> (official USP PDF) is here: https://www.usp.org/sites/default/files/usp/document/our-work/chemical-medicines/key-issues/232---2s_usp_35--final.pdf
Protocol-level takeaway: impurity controls should be tied to your risk assessment and route of administration. A topical product and an inhaled aerosol do not carry the same risk profile or justification expectations.
The research notes you provided are directionally correct: sponsors and CROs should expect procurement clauses requiring USP-conformant certificates, raw data access, and change-control notices.
This is not just a “quality culture” trend—it reflects a compliance reality: when results feed into IND amendments, safety reporting, or potential labeling discussions, sponsors must be able to demonstrate that analytical data are trustworthy.
When teams say “USP-aligned,” they often mean the supplier must support:
For electronic records and audit trails, 21 CFR Part 11 remains the key federal regulation for FDA-regulated electronic records/e-signatures (official eCFR): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
Operational takeaway: if your supplier cannot provide raw data or demonstrate audit trails, your program may face re-testing costs, timeline delays, or IND questions that could have been avoided.
Even when the product is “for clinical research,” sponsors should align procurement controls to the reality that the material can affect participant safety and study validity.
Sponsors and CROs should consider building a documented supplier program that covers:
A recurring theme in clinical supply failures is uncommunicated change: new cultivation lot, new extraction train, new analytical lab, new container, new excipient.
To reduce risk, procurement clauses increasingly require:
Federal policy signals and rescheduling discussions may evolve, but quality expectations for clinical research materials generally move in one direction: toward greater documentation, traceability, and patient-protective controls.
Even without making any predictions about scheduling outcomes, sponsors should plan for:
A practical way to reduce risk is to align internal SOPs and vendor contracts to recognized quality frameworks (USP, ICH, FDA guidance) so that program decisions remain defensible across regulatory scenarios.
If you support clinical investigations, here are high-impact steps you can take now to align with the direction of USP <1568>.
Ensure your internal product definition includes:
Tie validation acceptance criteria to how data will be used:
Move beyond “COA provided” to “COA + supporting package available on request,” and specify the turnaround times for audits and investigations.
Define what counts as a “major change” and what bridging evidence is required.
If you rely on electronic lab systems, ensure audit trails, access controls, and validation are addressed in vendor oversight.
This article is for informational purposes only and does not constitute legal advice. Clinical research programs should consult qualified counsel and regulatory experts for advice specific to their facts.
If your team is updating clinical supply SOPs, vendor qualification checklists, or COA/spec templates in response to USP <1568> and FDA’s clinical research quality guidance, use https://www.cannabisregulations.ai/ to track regulatory changes, standard-setting updates, and practical compliance workflows—so your next protocol amendment or supplier audit doesn’t become a fire drill.
